Forty Seven
Founders
Professor Irv Weissman, M.D. - Founder & Board Member
Mark McCamish, M.D., Ph.D. - CEO & Board member
Ravindra Majeti, M.D., Ph.D. - founder & board member
Mark Chao, M.D., Ph.D. - Founder & SVP, Head of Clinical Development
Jens-Peter Volkmer, M.D. - Founder & VP of R&D
Founded
2015
Stage
Seed
Invested
2015
Status
IPO
Lightspeed Team
Christopher Schaepe - Partner
Jonathan MacQuitty - Partner

With a passion to help patients defeat their cancer, Forty Seven is committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.

Company completed an IPO in 2018 and was acquired by Gilead Sciences, Inc. in 2020 for $4.9 billion.

Jonathan MacQuitty